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Background: Post transplant relapse remains a main cause
of transplant failure and mortality in patients with myelo-
dysplastic syndrome (MDS) and acute myelogenous
leukemia (AML). Azacitidine, a hypomethylating agent, has
been reported to reduce post transplant relapse in these
patients after unmodiﬁed allogeneic hematopoietic stem cell
transplantation (HSCT). There have been no reports of aza-
citidine use in patients undergoing T cell depleted (TCD)
HSCT.
Patients: Nine patients; 4 with high risk MDS, 1 with AML
evolved from MDS, 2 with therapy-related AML, and 2 with
de-novo AML, who had undergone TCD HSCT, were treated
with azacitidine post transplant. The dose of azacitidine, as
determined in a phase 1 study, was 32mg/m2 subcutane-
ously daily for 5 days monthly. All patients had been condi-
tioned with a myeloablative regimen of busulphan,
melphalan, ﬂudarabine and rabbit ATG and had received
a peripheral blood stem cell graft from a matched or mis-
matched related or unrelated donor.
Results: Seven patients were treated in complete remis-
sion as a prophylactic measure, one patient was treated in
relapse and one patient received, in addition to azaciti-
dine, a dose of DLI (0.5x106 CD3 cells/kg) for increasing
host chimerism and a new cytogenetic abnormality.
Treatment began at a median of 117 days post transplant
(range 80-333) and patients received a median of 3 cycles
(range 1-7). At a median of 8 months follow-up, 7 patients
were alive and 2 had died; one of pulmonary failure,
possibly secondary to busulphan and the other patient of
relapsed disease. In one patient, treatment was dis-
continued after development of an EBV-LPD while
receiving budesonide for upper GI GvHD, and in another
patient therapy was discontinued because of severe
pancytopenia secondary to adenovirus infection. A third
patient had treatment interruption after developing
dyspnea secondary to heart failure and chronic obstructive
lung disease. The patient with relapsed disease had
persistent pancytopenia throughout the treatment. In the
8 remaining patients, there were 4 with grade I anemia
and/or thrombocytopenia. Only one of the 8 patients
required G-CSF and azacitidine dose reduction (20%).
However, this patient's neutrophils were noted to decrease
prior to initiation of Azacitidine, possibly related to
treatment of an EBV-LPD with Rituxan. Two patients had
grade I skin GvHD and one patient had grade 1 upper GI
GvHD. Therapy with azacitidine did not worsen the
severity of GvHD.
Conclusions: This review shows that timely administration
of low dose azacitidine is feasible after TCD transplant in
patients with MDS and AML. The most common toxicity
related to azacitidine, myelosuppression, has been reported
only in patients who had concomitant viral infections. A
phase II trial will be conducted to assess the efﬁcacy of post
transplant azacitidine after TCD transplant.401
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Background: We have previously shown that lymphocyte
and monocyte recovery by 2-3 months post-allogeneic
hematopoietic (HCT) is associated with improved survival
in recipients of both myeloablative and reduced intensity
conditioning. Here, we test the hypothesis that the allo-
graft lymphocyte and monocyte content correlates with
recovery of those hematologic parameters prior to and at
day +100.
Methods: We pooled the hematologic recovery data,
including absolute lymphocyte and monocyte counts (ALC
and AMC, respectively) at day +15, +30, +60, and +100, and
outcomes data from our original cohorts of allogeneic HCT
recipients undergoing myeloablative or reduced intensity
(ﬂudarabine/melphalan). We included only those with
peripheral blood stem cell allografts and excluded thosewith
incomplete data regarding allograft leukocyte subset
content. 216 consecutive patients from 2000-2010 were
included in the analysis.
Results: Neither allograft lymphocyte, monocyte, gran-
ulocyte, nor CD34+ content correlated with hematologic
recovery parameters or overall survival in this cohort when
cell doses were analyzed as continuous variables or divided
in quartiles. No overall prognostic or optimal pattern of
allograft cellular content as determined by unsupervised
hierarchical clustering could be identiﬁed. With this pooled
data, prognostic factors for overall survival based on multi-
variate analysis included severity of chronic GVHD (P< .001),
development of post-transplant relapse (P ¼ .001), day +60
AMC > 0.3 x 109 cells/L (P ¼ .0015), and day +100 ALC > 0.3 x
109 cells/L (P < .001).
Conclusions: We conclude that, unlike in the autologous
HCT setting, post-allogeneic HCT lymphopenia and mono-
cytopenia appear to be related to complications and treat-
ment-related factors, and not related to allograft leukocyte
content.402
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Relapse remains a major problem after allogeneic stem
cell transplant (alloHSCT). There are limited data on the
outcomes after second alloHSCT. We conducted a single
institution retrospective review of 39 subjects who have
